Email: cspc@cspc.cn
News
News Center
Aug. 09
2024
VOLUNTARY ANNOUNCEMENT FIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020)OBTAINS CLINICAL TRIAL APPROVAL FOR NEW INDICATION
Jul. 15
CSPC Subsidiary Won the First Prize of Provincial Science and Technology Progress Award
Jul. 01
CSPC Listed in 2023 Top 100 Chinese Chemical Pharmaceutical Enterprises
Jun. 28
VOLUNTARY ANNOUNCEMENT - ENLONSTOBART INJECTION OBTAINS CONDITIONAL MARKETING APPROVAL GRANTED BY NMPA
VOLUNTARY ANNOUNCEMENT - PALBOCICLIB TABLETS OBTAINS DRUG REGISTRATION APPROVAL
TRACE-III Clinical Study of CSPC Mingfule Presented at European Stroke Organisation Conference
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
